Abstract
It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.
| Original language | English |
|---|---|
| Pages (from-to) | 352-360 |
| Number of pages | 9 |
| Journal | Glycobiology |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2012 Mar |
| Externally published | Yes |
Fingerprint
Keywords
- antibodies
- ganglioside complexes
- GBS
- lipid rafts
- neuropathies
ASJC Scopus subject areas
- Biochemistry
Cite this
Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. / Mauri, Laura; Casellato, Riccardo; Ciampa, Maria G.; Uekusa, Yoshinori; Kato, Koichi; Kaida, Ken Ichi; Motoyama, Mayumi; Kusunoki, Susumu; Sonnino, Sandro.
In: Glycobiology, Vol. 22, No. 3, 03.2012, p. 352-360.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a
AU - Mauri, Laura
AU - Casellato, Riccardo
AU - Ciampa, Maria G.
AU - Uekusa, Yoshinori
AU - Kato, Koichi
AU - Kaida, Ken Ichi
AU - Motoyama, Mayumi
AU - Kusunoki, Susumu
AU - Sonnino, Sandro
PY - 2012/3
Y1 - 2012/3
N2 - It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.
AB - It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.
KW - antibodies
KW - ganglioside complexes
KW - GBS
KW - lipid rafts
KW - neuropathies
UR - http://www.scopus.com/inward/record.url?scp=84856259019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856259019&partnerID=8YFLogxK
U2 - 10.1093/glycob/cwr139
DO - 10.1093/glycob/cwr139
M3 - Article
C2 - 21921061
AN - SCOPUS:84856259019
VL - 22
SP - 352
EP - 360
JO - Glycobiology
JF - Glycobiology
SN - 0959-6658
IS - 3
ER -